Cavalcante-Silva Luiz Henrique Agra, Sales-Neto José Marreiro de, Soares Mariana Mendonça, Ferreira Davi Azevedo, Medeiros Anna Beatriz Araujo, Rodrigues-Mascarenhas Sandra
Medical Sciences and Nursing Complex, Federal University of Alagoas, Arapiraca 57309-005, Brazil.
Biotechnology Center, Federal University of Paraíba, João Pessoa 58051-900, Brazil.
J Clin Med. 2025 Jun 11;14(12):4132. doi: 10.3390/jcm14124132.
Inflammatory bowel disease (IBD) is a chronic condition that significantly impairs the quality of life of millions of individuals. The pathogenesis of IBD is closely linked to dysbiosis of microbiota and the activation of various inflammatory pathways, which are characterized by elevated levels of activated immune cells, such as neutrophils and lymphocytes. While several therapeutic options, including corticosteroids and biologic agents, are available for the treatment of IBD, their efficacy remains limited. Consequently, the development of novel therapies is essential. In this context, cardiotonic steroids, a class of drugs traditionally known for their effects on the cardiovascular system, have gained attention due to their potential immunomodulatory properties. Thus, this review aims to explore the emerging therapeutic potential of cardiotonic steroids in the treatment of IBD.
炎症性肠病（IBD）是一种慢性疾病，严重影响着数百万患者的生活质量。IBD的发病机制与微生物群失调以及各种炎症途径的激活密切相关，其特征是活化免疫细胞（如中性粒细胞和淋巴细胞）水平升高。虽然有多种治疗选择，包括皮质类固醇和生物制剂可用于治疗IBD，但其疗效仍然有限。因此，开发新的治疗方法至关重要。在这种背景下，强心甾类药物，一类传统上因其对心血管系统的作用而闻名的药物，因其潜在的免疫调节特性而受到关注。因此，本综述旨在探讨强心甾类药物在治疗IBD方面新出现的治疗潜力。
